Literature DB >> 19005871

Efavirenz Mannich bases: synthesis, anti-HIV and antitubercular activities.

Dharmarajan Sriram1, Debjani Banerjee, Perumal Yogeeswari.   

Abstract

A series of efavirenz Mannich bases has been synthesized by reacting efavirenz, formaldehyde, and various aryl substituted piperazines using microwave irradiation (yield 35-88%). The synthesized compounds were evaluated for in-vitro anti-HIV and antimycobacterial activities. The in-vitro antiretroviral activities indicated that compound 7-(4-((6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2-oxo-2H-benzo[d] [1,3]oxazin-1 (4H)-yl)methyl)-3-methylpiperazin-l -yl)-1-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-4-oxoquinoline-3-carboxylic acid (4i) was equipotent to efavirenz with EC(50) of 2.4 nM. Compound 4i also inhibited M. tuberculosis with minimum inhibitory concentration of 0.2 microg/mL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19005871     DOI: 10.1080/14756360902784425

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  4 in total

1.  A highly sensitive ultra performance liquid chromatography-tandem mass spectrometric (UPLC-MS/MS) technique for quantitation of protein free and bound efavirenz (EFV) in human seminal and blood plasma.

Authors:  Lindsay B Avery; Teresa L Parsons; David J Meyers; Walter C Hubbard
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-10-08       Impact factor: 3.205

Review 2.  Mannich bases in medicinal chemistry and drug design.

Authors:  Gheorghe Roman
Journal:  Eur J Med Chem       Date:  2014-10-30       Impact factor: 6.514

Review 3.  Mannich bases: an important pharmacophore in present scenario.

Authors:  Suman Bala; Neha Sharma; Anu Kajal; Sunil Kamboj; Vipin Saini
Journal:  Int J Med Chem       Date:  2014-11-12

4.  Synthesis and in vitro antimicrobial activity screening of new pipemidic acid derivatives.

Authors:  Łukasz Popiołek; Anna Biernasiuk; Kinga Paruch; Anna Malm; Monika Wujec
Journal:  Arch Pharm Res       Date:  2018-04-04       Impact factor: 4.946

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.